Insig

Phys | September 21, 2017

Two new studies of green algae—the scourge of swimming pool owners and freshwater ponds—have revealed new insights into how these organisms siphon carbon dioxide from the air for use in photosynthesis, a key factor in their ability to grow so quickly. Understanding this process may someday help researchers improve the growth rate of crops such as wheat and rice....

Labiotech.eu | January 28, 2020

A Swiss research group has developed tiny plastic particles that could carry gene therapies to the center of the cell with less risk of getting attacked by the immune system than conventional gene therapies. The majority of gene therapies in use today are delivered to the DNA of target cells using viral vectors. While efficient at their job, viral vectors can risk triggering the immune system to destroy them. This can lead to the therapy becoming ineffective....

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

biotech | January 23, 2017

The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year, but midcap Incyte (INCY) is one of the few companies with potential blockbusters in its pipeline.Incyte closed out 2016 and started 2017 with some major developments. The first came late last year when the company discovered that its Jakafi drug won't be facing competition from Gilead(GILD) in 2018 as previously expected. Jakafi is used to treat two maladies: myelofibrosis, a bone marrow di...